Announcement under Regulation 30 (LODR), 2015 - Resignation of Chief Financial Officer
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. R Ramachandra has tendered his resignation as Chief Financial Officer of the company, effective from the close of business hours on May 31, 2026. He cited personal reasons for his decision, noting it was not made lightly. The resignation has been accepted by the Board of Directors in a meeting held on May 28, 2026. Mr. Ramachandra served as CFO for approximately 3.5 years. As a result, he will cease to be a Key Managerial Personnel (KMP) under Section 203 of the Companies Act, 2013. The company has stated appreciation for his valuable contributions during his tenure.
The departure of the CFO creates a leadership gap in the finance function. While the resignation is due to personal reasons (not performance issues), investors should monitor for the appointment of a new CFO, as this key role is critical for financial reporting and investor communications. The stock may see minor pressure until a replacement is announced.